Key Highlights

  • Revenue was USD 144.98 million against a USD 140.53 million estimate; Earnings were USD 0.37 per share against USD 0.30.
  • Net Revenue declined 2%, better than a guided 5% decline and the second quarter's 25% decline.
  • Gross Margin was 67.4% against 71.6%, while adjusted EBITDA of USD 22 million topped the outlook range.
  • Free Cash Flow was USD 10 million, and cash, cash equivalents and investments were USD 561 million.

ODDITY Tech Ltd. (NYSE:ODD) reported third quarter 2026 revenue of USD 144.98 million against an estimate of USD 140.53 million, a beat of about 3.2%. Earnings Per Share were USD 0.37 against an estimate of USD 0.30. The company reported before the market open on November 11, 2026, and held its Earnings Call that day.

Management said net revenue declined 2% from the prior year to USD 145 million, better than its outlook of approximately a 5% decline and a substantial sequential improvement from the 25% decline reported in the second quarter. More than 80% of third quarter net revenue came from repeat sales.

Margins, Cash Flow and Inventory

Gross margin was 67.4% against 71.6% in the prior year. Adjusted EBITDA, a non-GAAP measure, was USD 22 million, ahead of the outlook of USD 18 million to USD 20 million. Management said it remains disciplined on operating expenses while investing in ODDITY Labs, METHODIQ, a fourth Brand and its technology infrastructure.

Free cash flow was USD 10 million in the quarter, bringing free cash flow for the first nine months to approximately USD 3 million. The company exited the quarter with USD 561 million of cash, cash equivalents and investments.

Management said IL MAKIAGE continues to work through excess inventory from purchase commitments made in anticipation of stronger revenue, and that it plans to be in better inventory balance in 2027.

Management said SpoiledChild had an excellent third quarter and is projected by management to grow at least 35% for the year, approaching USD 350 million of revenue, for a brand that launched less than five years ago. It said the success of SpoiledChild and METHODIQ shows the strength of its platform, with three distinct brands today, each with potential to reach billion dollar revenue.

Management said it plans to launch six additional peptide therapies covered by the enforcement discretion policy published by a federal health agency last month. It said its slate of launches planned for 2027 across all brands is the most exciting it has had, and that a fourth brand is planned to be ready for launch in 2027, with timing details closer to launch.

Raised Outlook

Management said it is raising its revenue and adjusted EBITDA outlook for 2026, and that it now anticipates full year net revenue declining approximately 18.5%. Management's statements about product launches, regulatory policy and brand potential are forward looking.

Items to Follow

The items to follow are repeat sales, gross margin, the inventory position at IL MAKIAGE, the growth of its newer brands and the delivery of the raised outlook. The company's legal proceedings, regulatory matters and related disclosures are flagged for human legal review.